Three-Year Follow-up and Event Rates in the International Reduction of Atherothrombosis for Continued Health Registry
Resource
EUROPEAN HEART JOURNAL v.30 n.19 pp.2318-2326
Journal
European Heart Journal
Pages
2318-2326
Date Issued
2009
Date
2009
Author(s)
Alberts, M. J.
Bhatt, D. L.
Mas, J.-L.
Ohman, E. M.
Hirsch, A. T.
Rother, J.
Salette, G.
Goto, S.
Smith, S. C.
Liau, C.-S.
Wilson, P. W.F.
Steg, Ph. G.
Abstract
To determine 3-year event rates in outpatients with vascular disease enrolled in the REduction of Atherothrombosis for Continued Health (REACH) Registry. Methods and results REACH enrolled 67 888 outpatients with atherothrombosis [ established coronary artery disease (CAD), cerebrovascutar disease, or peripheral arterial disease (PAD)], or with at least three atherothrombotic risk factors, from 44 countries . Among the 55 499 patients at baseline with symptomatic disease, 39 675 were eligible for 3-year follow-up, and 32 247 had data available (81% retention rate). Among the symptomatic patients at 3 years, 92% were taking an antithrombotic agent, 91% an anti hypertensive, and 76% were on Upid- lowering therapy. For myocardial infarction (Ml)/ stroke/vascutar death, 1 - and 3-year event rates for all patients were 4.2 and 11.0%, respectively. Event rates (MI/ stroke/vascutar death) were significantly higher for patients with symptomatic disease vs. those with risk factors only at 1 year (4.7 vs. 2.3%, P < 0.001) and at 3 years (12.0 vs. 6.0%, P < 0.001). One and 3-year rates of MI /stroke/vascular cleath/ rehospitatization were 14.4 and 28.4 %, respectively, for patients with symptomatic disease. Rehospitalization for a vascular event other than Mi/ stroke/ vascular death was common at 3 years (19.0% overall; 33.6% for PAD ; 23.0% for CAD). For patients with symptomatic vascular disease in one vascular bed vs. multiple vascular beds, 3-year event rates for MI/stroke/ vascular death/ rehospitalization were 25.5 vs. 40.5% (P < 0.001). Conclusion Despite contemporary therapy, outpatients with symptomatic atherothrombotic vascular disease experience high rates of recurrent vascular events and rehospitalizations.
Subjects
Atherothrombosis
Risk factors
Coronary artery disease
Cerebrovascular disease
Peripheral arterial disease
SDGs
Other Subjects
acetylsalicylic acid; anticoagulant agent; antidiabetic agent; antihypertensive agent; antilipemic agent; antithrombocytic agent; hydroxymethylglutaryl coenzyme A reductase inhibitor; aged; artery disease; article; cardiovascular risk; cerebrovascular disease; coronary artery disease; female; follow up; heart infarction; hospital readmission; human; major clinical study; male; priority journal; recurrent disease; stroke; vascular disease; Aged; Ambulatory Care; Anticoagulants; Antihypertensive Agents; Coronary Artery Disease; Diabetes Complications; Female; Follow-Up Studies; Hospitalization; Humans; Hypertension; Hypoglycemic Agents; Male; Myocardial Infarction; Obesity; Peripheral Vascular Diseases; Recurrence; Registries; Risk Factors; Smoking; Stroke
Type
journal article